160
Participants
Start Date
May 10, 2021
Primary Completion Date
December 30, 2025
Study Completion Date
December 31, 2025
SLS009
Solution for injection
venetoclax
Tablets
azacitidine
Solution for injection
TERMINATED
New York - Presbyterian Hospital, New York
TERMINATED
Clinical Research Alliance, Inc., Lake Success
RECRUITING
UNC School of Medicine, Division of Hematology, Chapel Hill
RECRUITING
Bon Secours St. Francis Cancer Center, Greenville
RECRUITING
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
TERMINATED
Ochsner Clinic Foundation, New Orleans
RECRUITING
Baylor Scott & White Health, Dallas
RECRUITING
MD Anderson, Houston
COMPLETED
Blood disease hospital, Chinese Academy of Medical Science, Tianjin
COMPLETED
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou
COMPLETED
Henan Cancer Hospital, Zhengzhou
COMPLETED
The First Affiliated Hospital of Bengbu Medical College, Bengbu
COMPLETED
Anhui Provincial Hospital, Hefei
WITHDRAWN
Affiliated Cancer Hospital of Chongqing University, Chongqing
COMPLETED
Cancer prevention and treatment center of Sun Yat sen University, Guangzhou
COMPLETED
Guangdong Provincial People's Hospital, Guangzhou
COMPLETED
Affiliated Hospital of Hebei University, Baoding
COMPLETED
The First Affiliated Hospital of Soochow University, Suzhou
COMPLETED
The First Affiliated Hospital Of Nanchang University, Nanchang
COMPLETED
Shengjing Hospital Affiliated to China Medical University, Shenyang
COMPLETED
Linyi Cancer Hospital, Linyi
Lead Sponsor
Sellas Life Sciences Group
INDUSTRY